Literature DB >> 30060213

Testosterone Levels in Third Trimester in Polycystic Ovary Syndrome: Odense Child Cohort.

Dorte Glintborg1, Richard Christian Jensen1,2, Kristian Bentsen1, Anne Vibeke Schmedes3, Ivan Brandslund3,4, Henriette Boye Kyhl5,6, Niels Bilenberg7, Marianne Skovsager Andersen1.   

Abstract

Background: Polycystic ovary syndrome (PCOS) is characterized by hyperandrogenism. In pregnancy, testosterone levels may be higher in women with PCOS compared with controls. Aims: To compare total testosterone (TT), free testosterone (FT), and sex hormone-binding globulin (SHBG) levels in third-trimester pregnant women with PCOS and controls and to establish reference ranges for TT, FT, and SHBG in PCOS and controls.
Methods: The study was part of the prospective study, Odense Child Cohort. PCOS was diagnosed by questionnaires and/or patient records. Fasting blood samples were collected at gestational week 28 and plasma TT was measured by liquid chromatography-tandem mass spectrometry in women with PCOS (n = 145) and in women without PCOS (controls, n = 1341).
Results: Levels of TT (mean, 2.4 vs 2.0 nmol/L) and FT (mean, 0.005 vs 0.004 nmol/L) were higher, whereas SHBG levels (mean, 447 vs 477 nmol/L) were lower in women with PCOS vs controls (all P < 0.001). Reference intervals for TT, FT, and SHBG in women with PCOS and controls were overlapping, and partitioning of reference intervals was an ambiguous decision. In multiple regression analyses, TT and FT levels were positively associated with PCOS status and BMI and inversely associated with age and parity. Offspring sex did not predict maternal TT and FT. Conclusions: TT and FT levels were higher in third-trimester pregnant women with PCOS compared with controls. Separate reference interval for FT in women with PCOS should be considered.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30060213     DOI: 10.1210/jc.2018-00889

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

Review 1.  A Narrative Review of Placental Contribution to Adverse Pregnancy Outcomes in Women With Polycystic Ovary Syndrome.

Authors:  Angela S Kelley; Yolanda R Smith; Vasantha Padmanabhan
Journal:  J Clin Endocrinol Metab       Date:  2019-11-01       Impact factor: 5.958

2.  Recurrent maternal virilization during pregnancy in patients with PCOS: two clinical cases.

Authors:  M Deknuydt; A Dumont; A Bruyneel; D Dewailly; S Catteau-Jonard
Journal:  Reprod Biol Endocrinol       Date:  2018-10-30       Impact factor: 5.211

3.  Prenatal androgen exposure causes a sexually dimorphic transgenerational increase in offspring susceptibility to anxiety disorders.

Authors:  Sanjiv Risal; Maria Manti; Haojiang Lu; Romina Fornes; Henrik Larsson; Anna Benrick; Qiaolin Deng; Carolyn E Cesta; Mina A Rosenqvist; Elisabet Stener-Victorin
Journal:  Transl Psychiatry       Date:  2021-01-13       Impact factor: 6.222

4.  Maternal Testosterone Concentrations in Third Trimester and Offspring Handgrip Strength at 5 Years: Odense Child Cohort.

Authors:  Malene Dybdahl; Christine Dalgård; Dorte Glintborg; Marianne Skovsager Andersen; Henrik Thybo Christesen
Journal:  J Clin Endocrinol Metab       Date:  2022-06-16       Impact factor: 6.134

5.  Sustained Maternal Hyperandrogenism During PCOS Pregnancy Reduced by Metformin in Non-obese Women Carrying a Male Fetus.

Authors:  Frida Andræ; David Abbott; Solhild Stridsklev; Anne Vibeke Schmedes; Ingrid Hov Odsæter; Eszter Vanky; Øyvind Salvesen
Journal:  J Clin Endocrinol Metab       Date:  2020-12-01       Impact factor: 5.958

6.  Increased uterine androgen receptor protein abundance results in implantation and mitochondrial defects in pregnant rats with hyperandrogenism and insulin resistance.

Authors:  Yuehui Zhang; Min Hu; Fan Yang; Yizhuo Zhang; Shuting Ma; Dongqi Zhang; Xu Wang; Amanda Nancy Sferruzzi-Perri; Xiaoke Wu; Mats Brännström; Linus R Shao; Håkan Billig
Journal:  J Mol Med (Berl)       Date:  2021-06-28       Impact factor: 4.599

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.